Cue Biopharma, Inc. (CUE)
CUE moved a median of -0.05% 30 minutes after news, and -1.24% by the close. How CUE actually reacts to news — the realized, point-in-time move the market made, measured across 251 labeled events over the last three years with zero look-ahead.
CUE’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.50% | 58% | 247 |
| 30-min | -0.05% | 50% | 250 |
| 60-min | -0.53% | 43% | 250 |
| to close | -1.24% | 41% | 246 |
| Middle 50% of CUE reactions | -2.91% to +2.54% |
|---|---|
| Median reaction (30-min) | -0.05% |
| Measured reactions | 251 |
Half of all Cue Biopharma, Inc. news events land between -2.91% and +2.54% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when CUE moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to CUE's baseline. Nothing else.
Recent CUE events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 8-K Cue Biopharma, Inc. For: Sep 20 | SEC filing · Form 8-K | SEC EDGAR | -0.91% | -26.57% | |
| Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria | Press release | GlobeNewswire | -0.91% | -26.57% | |
| Form EFFECT Cue Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +1.76% | -6.14% | |
| Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights | Press release | GlobeNewswire | +5.60% | -11.27% | |
| Form 10-Q Cue Biopharma, Inc. For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.60% | -11.27% | |
| Form 8-K Cue Biopharma, Inc. For: Aug 14 | SEC filing · Form 8-K | SEC EDGAR | +5.60% | -11.27% | |
| Form S-3 Cue Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -3.06% | +5.71% | |
| Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission | Press release | GlobeNewswire | +1.39% | -0.48% | |
| Form 8-K Cue Biopharma, Inc. For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | +0.07% | -1.19% | |
| Form D Cue Biopharma, Inc. | SEC filing · Form D | SEC EDGAR | — | +1.45% | |
| Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development | Press release | GlobeNewswire | -1.22% | -12.97% | |
| Form 8-K Cue Biopharma, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -1.22% | -12.97% | |
| Cue Biopharma Announces $50.0 Million Private Placement | Press release | GlobeNewswire | +2.16% | -9.34% | |
| Form EFFECT Cue Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | -2.55% | |
| Form EFFECT Cue Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | +5.63% | +8.25% | |
| Form S-3 Cue Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -2.94% | +10.86% | |
| Form 8-K Cue Biopharma, Inc. For: Jun 01 | SEC filing · Form 8-K | SEC EDGAR | +0.50% | +9.78% | |
| Form S-3 Cue Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | +0.50% | +9.78% | |
| Form S-8 Cue Biopharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | +0.50% | +9.78% | |
| Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution | Press release | GlobeNewswire | +2.30% | -3.31% | |
| Form 8-K Cue Biopharma, Inc. For: May 29 | SEC filing · Form 8-K | SEC EDGAR | +2.30% | -3.31% | |
| Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | +0.89% | +8.87% | |
| Form DEF 14A Cue Biopharma, Inc. For: Jun 01 | SEC filing · Form DEF | SEC EDGAR | -5.44% | +1.31% | |
| Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments | Press release | GlobeNewswire | +1.24% | -1.29% | |
| Form 10-Q Cue Biopharma, Inc. For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | +1.24% | -1.29% | |
| Form 8-K Cue Biopharma, Inc. For: May 14 | SEC filing · Form 8-K | SEC EDGAR | +1.24% | -1.29% | |
| Form D Cue Biopharma, Inc. | SEC filing · Form D | SEC EDGAR | +1.24% | -1.29% | |
| Form PRE 14A Cue Biopharma, Inc. For: Jun 01 | SEC filing · Form PRE | SEC EDGAR | -2.15% | -4.88% | |
| Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | GlobeNewswire | +1.07% | -0.99% | |
| Form 8-K Cue Biopharma, Inc. For: Apr 27 | SEC filing · Form 8-K | SEC EDGAR | +2.49% | +12.31% | |
| Form S-8 Cue Biopharma, Inc. | SEC filing · Form S-8 | SEC EDGAR | -3.65% | +8.22% | |
| Cue Biopharma Announces $30 Million Private Placement | Press release | GlobeNewswire | -7.53% | -8.89% | |
| Cue Biopharma Expands Pipeline with Exclusive License from Ascendant Health Sciences Ltd. for Clinical-Stage Dual-Mechanism Anti-IgE Antibody | Press release | GlobeNewswire | -7.53% | -8.89% | |
| Cue Biopharma Names Shao-Lee Lin M.D., Ph.D., CEO, President and Board Director to Lead Continued Growth and Transformation into a Clinical-Stage Company | Press release | GlobeNewswire | -7.53% | -8.89% | |
| Cue Biopharma Announces 1-for-30 Reverse Stock Split | Press release | GlobeNewswire | +9.22% | +16.02% | |
| Form 8-K Cue Biopharma, Inc. For: Apr 22 | SEC filing · Form 8-K | SEC EDGAR | +9.22% | +16.02% | |
| Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026 | Press release | GlobeNewswire | +11.79% | +72.45% | |
| Form 8-K Cue Biopharma, Inc. For: Apr 13 | SEC filing · Form 8-K | SEC EDGAR | +7.72% | +12.34% | |
| Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement | Press release | GlobeNewswire | -3.15% | +46.42% | |
| Form 8-K Cue Biopharma, Inc. For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | +2.06% | |
| Form EFFECT Cue Biopharma, Inc. | SEC filing · Form EFFECT | SEC EDGAR | -3.42% | -10.07% | |
| Cue Biopharma Announces CEO Transition | Press release | GlobeNewswire | +0.58% | +0.44% | |
| Form 8-K Cue Biopharma, Inc. For: Mar 23 | SEC filing · Form 8-K | SEC EDGAR | +0.58% | +0.44% | |
| Form DEFA14A Cue Biopharma, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.58% | +0.44% | |
| Cue Biopharma to Host Virtual R&D Day Event on April 7, 2026 | Press release | GlobeNewswire | -2.99% | -2.64% | |
| Form S-3 Cue Biopharma, Inc. | SEC filing · Form S-3 | SEC EDGAR | -0.66% | -5.40% | |
| Cue Biopharma Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Press release | GlobeNewswire | -3.06% | -8.59% | |
| Form 10-K Cue Biopharma, Inc. For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.06% | -8.59% | |
| Form 8-K Cue Biopharma, Inc. For: Mar 16 | SEC filing · Form 8-K | SEC EDGAR | -3.06% | -8.59% | |
| Form ARS Cue Biopharma, Inc. For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -3.06% | -8.59% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the CUE section they belong to.
Where else CUE is measured.
CUE earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Nevro Corp. (NVRO) | 253 | 0.00% | 49% |
| DarioHealth Corp. (DRIO) | 252 | 0.00% | 45% |
| DOVA PHARMACEUTICALS (DOVA) | 251 | -0.10% | 46% |
| Krystal Biotech, Inc. (KRYS) | 251 | +0.05% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Cue Biopharma, Inc.'s median reaction calculated?
Every labeled CUE news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 251 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of CUE's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does CUE's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.